Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...
Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS≥6 treated with LT3001. * These data suggest that LT3001 has the potential to provide significant clinica...
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA
TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, fromSingapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approv...
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US
TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...
Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke
TAIPEI, , June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability and ...
Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals
TAIPEI, and GROTON, Conn., Jan. 16, 2018 /PRNewswire/ -- Lumosa Therapeutics (Lumosa, 6535.TWO), a new drug development company inTaiwan, and Skyline Vet Pharma (SVP), an emerging animal health company in theUSA, today announced a licensing agreement for Lumosa's CS011.According to the terms, SV...
First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke
TAIPEI, , July 31, 2017 /PRNewswire/ -- Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce the enrollment of the first subject for the Phase 1 clinical trial of its new drug candidate, LT3001, for acute ischemic stroke. The first human subject was dosed wi...